DE602007013648D1 - Tartratsalz aus Isofagomin und Verwendungsverfahren dafür - Google Patents
Tartratsalz aus Isofagomin und Verwendungsverfahren dafürInfo
- Publication number
- DE602007013648D1 DE602007013648D1 DE602007013648T DE602007013648T DE602007013648D1 DE 602007013648 D1 DE602007013648 D1 DE 602007013648D1 DE 602007013648 T DE602007013648 T DE 602007013648T DE 602007013648 T DE602007013648 T DE 602007013648T DE 602007013648 D1 DE602007013648 D1 DE 602007013648D1
- Authority
- DE
- Germany
- Prior art keywords
- isofagomine
- salt
- tartrate salt
- gaucher disease
- isofagomine tartrate
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 150000003892 tartrate salts Chemical class 0.000 title abstract 2
- QPYJXFZUIJOGNX-HSUXUTPPSA-N afegostat Chemical compound OC[C@H]1CNC[C@@H](O)[C@@H]1O QPYJXFZUIJOGNX-HSUXUTPPSA-N 0.000 title 1
- ULBPPCHRAVUQMC-MUMXBIPUSA-N (2r,3r)-2,3-dihydroxybutanedioic acid;(3r,4r,5r)-5-(hydroxymethyl)piperidine-3,4-diol Chemical compound OC[C@H]1CNC[C@@H](O)[C@@H]1O.OC(=O)[C@H](O)[C@@H](O)C(O)=O ULBPPCHRAVUQMC-MUMXBIPUSA-N 0.000 abstract 2
- 208000015872 Gaucher disease Diseases 0.000 abstract 2
- 150000003839 salts Chemical class 0.000 abstract 2
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D211/40—Oxygen atoms
- C07D211/44—Oxygen atoms attached in position 4
- C07D211/46—Oxygen atoms attached in position 4 having a hydrogen atom as the second substituent in position 4
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Engineering & Computer Science (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Emergency Medicine (AREA)
- Endocrinology (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Hydrogenated Pyridines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Cephalosporin Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US80802006P | 2006-05-24 | 2006-05-24 | |
| US89071907P | 2007-02-20 | 2007-02-20 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DE602007013648D1 true DE602007013648D1 (de) | 2011-05-19 |
Family
ID=38462442
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DE602007013648T Active DE602007013648D1 (de) | 2006-05-24 | 2007-05-23 | Tartratsalz aus Isofagomin und Verwendungsverfahren dafür |
Country Status (14)
| Country | Link |
|---|---|
| US (2) | US7501439B2 (enExample) |
| EP (1) | EP1860101B1 (enExample) |
| JP (1) | JP5292605B2 (enExample) |
| AT (1) | ATE504570T1 (enExample) |
| AU (1) | AU2007202359B2 (enExample) |
| BR (1) | BRPI0706114A2 (enExample) |
| CA (1) | CA2590122C (enExample) |
| DE (1) | DE602007013648D1 (enExample) |
| DK (1) | DK1860101T3 (enExample) |
| IL (1) | IL183415A (enExample) |
| MX (1) | MX2007006175A (enExample) |
| PL (1) | PL1860101T3 (enExample) |
| PT (1) | PT1860101E (enExample) |
| WO (1) | WO2007140212A2 (enExample) |
Families Citing this family (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2006254796B2 (en) * | 2005-06-08 | 2012-08-16 | Amicus Therapeutics, Inc. | Treatment of CNS disorders associated with mutations in genes encoding lysosomal enzymes |
| BRPI0713442A2 (pt) | 2006-06-23 | 2012-03-06 | Amicus Therapeutics, Inc. | Método para o tratamento de desrodens neurológicas, pelo aumento da atividade de b-glicocerebrosidase |
| WO2008144773A1 (en) | 2007-05-22 | 2008-11-27 | Amicus Therapeutics, Inc. | New method for preparing isofagomine and its derivatives |
| WO2009102895A2 (en) | 2008-02-12 | 2009-08-20 | Amicus Therapeutics, Inc. | Method to predict response to pharmacological chaperone treatment of diseases |
| AU2009314447A1 (en) * | 2008-11-14 | 2010-05-20 | Neuraltus Pharmaceuticals, Inc. | Compositions and methods for the treatment of altered alpha-synuclein function |
| CN109172813B (zh) | 2009-07-28 | 2022-09-02 | 武田药品工业株式会社 | 用于治疗戈谢病的组合物和方法 |
| RU2608520C2 (ru) * | 2009-10-19 | 2017-01-19 | Амикус Терапьютикс, Инк. | Новые композиции для предупреждения и/или лечения лизосомных болезней накопления |
| LT2490532T (lt) | 2009-10-19 | 2017-03-27 | Amicus Therapeutics, Inc. | Naujos kompozicijos centrinės nervų sistemos degeneratyvinių sutrikimų profilaktikai ir (arba) gydymui |
| DK2707101T3 (da) | 2011-05-12 | 2019-05-13 | Proteostasis Therapeutics Inc | Proteostaseregulatorer |
| WO2012177997A1 (en) | 2011-06-22 | 2012-12-27 | The General Hospital Corporation | Treatment of proteinopathies |
| AU2013202368B2 (en) | 2012-01-25 | 2016-06-16 | Proteostasis Therapeutics, Inc. | Proteasome activity modulating compounds |
| AU2013225816B2 (en) | 2012-03-02 | 2017-10-26 | Takeda Pharmaceutical Company Limited | Compositions and methods for treating Type III Gaucher Disease |
| ES2924829T3 (es) | 2012-03-27 | 2022-10-11 | Amicus Therapeutics Inc | Compuestos novedosos para prevenir y/o tratar tesaurismosis lisosómicas y/o trastornos degenerativos del sistema nervioso central |
| JP2015512913A (ja) | 2012-03-28 | 2015-04-30 | ザ ユナイテッド ステイツ オブ アメリカ， アズ リプレゼンテッド バイ ザ セクレタリー， デパートメント オブ ヘルス アンド ヒューマン サービシーズ | グルコセレブロシダーゼ活性剤として有用なサリチル酸誘導体 |
| EP3318277A1 (en) | 2016-11-04 | 2018-05-09 | Institut du Cerveau et de la Moelle Epiniere-ICM | Inhibitors of glucosylceramide synthase for the treatment of motor neuron diseases |
| DE102017103346A1 (de) * | 2017-02-17 | 2018-08-23 | Lts Lohmann Therapie-Systeme Ag | Strukturierte orodispergierbare Filme |
| CN111278439A (zh) * | 2017-10-26 | 2020-06-12 | 夏尔人类遗传性治疗公司 | 包含葡萄糖脑苷脂酶和异烟肼的调配物 |
| MX2020014082A (es) | 2018-06-27 | 2021-04-13 | Proteostasis Therapeutics Inc | Compuestos que mejoran la actividad del proteasoma. |
| JP7551087B2 (ja) | 2018-06-27 | 2024-09-17 | キネタ， インコーポレイテッド | プロテアソーム活性増強化合物 |
| WO2020023390A1 (en) | 2018-07-25 | 2020-01-30 | Modernatx, Inc. | Mrna based enzyme replacement therapy combined with a pharmacological chaperone for the treatment of lysosomal storage disorders |
| JP7642561B2 (ja) * | 2019-04-25 | 2025-03-10 | 武田薬品工業株式会社 | イソファゴミン塩、その使用方法および製剤 |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5844102A (en) * | 1994-07-07 | 1998-12-01 | University Of Maryland Baltimore County | Glycohydrolase inhibitors, their preparation and use thereof |
| US6274597B1 (en) * | 1998-06-01 | 2001-08-14 | Mount Sinai School Of Medicine Of New York University | Method of enhancing lysosomal α-Galactosidase A |
-
2007
- 2007-05-23 PL PL07252109T patent/PL1860101T3/pl unknown
- 2007-05-23 DE DE602007013648T patent/DE602007013648D1/de active Active
- 2007-05-23 US US11/752,658 patent/US7501439B2/en active Active
- 2007-05-23 EP EP07252109A patent/EP1860101B1/en not_active Not-in-force
- 2007-05-23 AT AT07252109T patent/ATE504570T1/de active
- 2007-05-23 PT PT07252109T patent/PT1860101E/pt unknown
- 2007-05-23 DK DK07252109.9T patent/DK1860101T3/da active
- 2007-05-23 WO PCT/US2007/069550 patent/WO2007140212A2/en not_active Ceased
- 2007-05-23 MX MX2007006175A patent/MX2007006175A/es active IP Right Grant
- 2007-05-24 CA CA 2590122 patent/CA2590122C/en not_active Expired - Fee Related
- 2007-05-24 AU AU2007202359A patent/AU2007202359B2/en not_active Ceased
- 2007-05-24 IL IL183415A patent/IL183415A/en active IP Right Grant
- 2007-05-24 JP JP2007138358A patent/JP5292605B2/ja not_active Expired - Fee Related
- 2007-05-24 BR BRPI0706114-5A patent/BRPI0706114A2/pt not_active Application Discontinuation
-
2009
- 2009-02-23 US US12/391,049 patent/US7863453B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| US20070281975A1 (en) | 2007-12-06 |
| EP1860101B1 (en) | 2011-04-06 |
| WO2007140212A2 (en) | 2007-12-06 |
| JP5292605B2 (ja) | 2013-09-18 |
| AU2007202359B2 (en) | 2012-02-16 |
| IL183415A0 (en) | 2007-09-20 |
| US7863453B2 (en) | 2011-01-04 |
| CA2590122A1 (en) | 2007-11-24 |
| BRPI0706114A2 (pt) | 2008-11-18 |
| US20090176830A1 (en) | 2009-07-09 |
| CA2590122C (en) | 2015-03-31 |
| MX2007006175A (es) | 2009-02-16 |
| US7501439B2 (en) | 2009-03-10 |
| PT1860101E (pt) | 2011-07-12 |
| ATE504570T1 (de) | 2011-04-15 |
| EP1860101A1 (en) | 2007-11-28 |
| JP2007314540A (ja) | 2007-12-06 |
| IL183415A (en) | 2012-03-29 |
| DK1860101T3 (da) | 2011-07-25 |
| PL1860101T3 (pl) | 2011-10-31 |
| WO2007140212A3 (en) | 2008-12-24 |
| AU2007202359A1 (en) | 2007-12-13 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DE602007013648D1 (de) | Tartratsalz aus Isofagomin und Verwendungsverfahren dafür | |
| MX350898B (es) | Sal de malato de n(4-{[6,7-bis(metiloxi) quinolin-4-il]oxi}fenil)- n'-(4-fluorofenil)ciclopropano-1,1-dicarboxamida, y sus formas cristalinas para el tratamiento de cancer. | |
| ATE530519T1 (de) | Cyclobutylaminderivate | |
| NO343929B3 (no) | 1-[2-(2,4-dimetylfenylsulfanyl-fenyl]-piperazin som en forbindelse med kombinert serotoninreopptak, 5-HT3- og 5HT1A-aktivitet for behandlingen av kognitiv smerte | |
| DE602004029580D1 (de) | Substituierte indolderivate für eine pharmazeutische zusammensetzung zur behandlung von atemwegserkrankungen | |
| NO20070470L (no) | Sammensetninger og fremgangsmater for behandling av dyslipidemi | |
| WO2005075425A3 (en) | Substituted bisarylurea derivatives as kinase inhibitors | |
| NZ599343A (en) | Substituted piperidines that increase p53 activity and the uses thereof | |
| NO20081905L (no) | Benzotiazolcyklobutylaminderivater og deres anvendelse som histamin-3-reseptorligander | |
| NO20075111L (no) | Farmasoytisk sammensetning | |
| ATE476414T1 (de) | Biphenyloxyessigsäurederivate zur behandlung von atemwegserkrankungen | |
| ATE545637T1 (de) | Substituierte diphenylether, -amine, -sulfide und methane zur behandlung von atemwegserkrankungen | |
| ATE534391T1 (de) | 3,11b-cis-dihydrotetrabenazin zur behandlung von psychosen | |
| PL1960379T3 (pl) | Pochodne N-(1-alkilo-2-fenyloetylo)-karboksamidu i ich zastosowanie jako fungicydów | |
| ATE441632T1 (de) | Gesättigte und ungesättigte 3-pyridyl- benzocycloalkylmethyl-amine zur behandlung von schmerzen, depressionen und angstzuständen | |
| DE602006013271D1 (de) | Verfahren zur herstellung von 4-(phenoxy-5-methyl-pyrimidin-4-yloxy)piperidin-1-carboxylsäure-derivaten und damit zusammenhängenden verbindungen | |
| UA88481C2 (ru) | Донепезила фумарат, пригодный для получения фармацевтических композиций | |
| MX2009003974A (es) | N-(2-hidroxietil)-n-metil-4-(quinolin-8-il(1-(tiazol-4-ilmetil)pi peridin-4-ilideno)metil)benzamida, el proceso para su sintesis, asi como su uso para el tratamiento del dolor, la ansiedad y la depresion. | |
| DE502006003194D1 (de) | Salze substituierter allophansäureester und deren verwendung in arzneimitteln | |
| ATE439831T1 (de) | Stabile kristalline form von bifeprunoxmesylat, dosierungsformen davon und verfahren zu deren verwendung | |
| UA94042C2 (ru) | Применение агомелатина в получении лекарственных средств, предназначенных для лечения синдрома смита-магениса | |
| CY1110156T1 (el) | Υποκατεστημενες ενωσεις 4,5,6,7-τετραϋδρο-βενζοθειαζολ-2-υλαμινης | |
| GB0514811D0 (en) | Compounds | |
| ATE546159T1 (de) | Neue arzneimittelkombinationen zur behandlung von atemwegserkrankungen enthaltend langwirksame beta-2-agonisten und wenigstens einen weiteren wirkstoff | |
| ATE527997T1 (de) | Verwendung von aminapthon zur herstellung eines medikaments zur behandlung von arteriopathien |